- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00326105
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders (PEARL)
24. mars 2009 oppdatert av: AstraZeneca
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment (PEARL STUDY)
The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Forventet)
450
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater
- Research Site
-
-
California
-
El Centro, California, Forente stater
- Research Site
-
Irvine, California, Forente stater
- Research Site
-
Oceanside, California, Forente stater
- Research Site
-
San Diego, California, Forente stater
- Research Site
-
-
Colorado
-
Pueblo, Colorado, Forente stater
- Research Site
-
-
Florida
-
Coral Springs, Florida, Forente stater
- Research Site
-
Deland, Florida, Forente stater
- Research Site
-
Gainsville, Florida, Forente stater
- Research Site
-
Hialeah, Florida, Forente stater
- Research Site
-
Jacksonville, Florida, Forente stater
- Research Site
-
Miami, Florida, Forente stater
- Research Site
-
Orlando, Florida, Forente stater
- Research Site
-
West Palm Beach, Florida, Forente stater
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forente stater
- Research Site
-
Roswell, Georgia, Forente stater
- Research Site
-
-
Illinois
-
Hoffman Estates, Illinois, Forente stater
- Research Site
-
Naperville, Illinois, Forente stater
- Research Site
-
Oak Brook, Illinois, Forente stater
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Forente stater
- Research Site
-
Lafayette, Indiana, Forente stater
- Research Site
-
Valparaiso, Indiana, Forente stater
- Research Site
-
-
Kansas
-
Prairie Village, Kansas, Forente stater
- Research Site
-
Wichita, Kansas, Forente stater
- Research Site
-
-
Louisiana
-
Shreveport, Louisiana, Forente stater
- Research Site
-
-
Maryland
-
Glen Burnie, Maryland, Forente stater
- Research Site
-
-
Massachusetts
-
Braintree, Massachusetts, Forente stater
- Research Site
-
Springfield, Massachusetts, Forente stater
- Research Site
-
-
Michigan
-
Clinton Township, Michigan, Forente stater
- Research Site
-
Kalamazoo, Michigan, Forente stater
- Research Site
-
Royal Oak, Michigan, Forente stater
- Research Site
-
-
Missouri
-
St Charles, Missouri, Forente stater
- Research Site
-
St. Louis, Missouri, Forente stater
- Research Site
-
-
New Jersey
-
Cherry Hill, New Jersey, Forente stater
- Research Site
-
Clementon, New Jersey, Forente stater
- Research Site
-
-
New York
-
Cedarhurst, New York, Forente stater
- Research Site
-
New York, New York, Forente stater
- Research Site
-
Olean, New York, Forente stater
- Research Site
-
Rochester, New York, Forente stater
- Research Site
-
Staten Island, New York, Forente stater
- Research Site
-
-
Ohio
-
Beechwood, Ohio, Forente stater
- Research Site
-
Toledo, Ohio, Forente stater
- Research Site
-
-
Oklahoma
-
Norman, Oklahoma, Forente stater
- Research Site
-
Oklahoma City, Oklahoma, Forente stater
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater
- Research Site
-
-
Rhode Island
-
Lincoln, Rhode Island, Forente stater
- Research Site
-
-
South Carolina
-
Columbia, South Carolina, Forente stater
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, Forente stater
- Research Site
-
-
Texas
-
Friendswood, Texas, Forente stater
- Research Site
-
Houston, Texas, Forente stater
- Research Site
-
San Antonio, Texas, Forente stater
- Research Site
-
Wichita Falls, Texas, Forente stater
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Forente stater
- Research Site
-
-
Virginia
-
Arlington, Virginia, Forente stater
- Research Site
-
Richmond, Virginia, Forente stater
- Research Site
-
-
Washington
-
Bellevue, Washington, Forente stater
- Research Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patient is able to provide written informed consent before beginning any study related procedures
- Patient has a documented clinical diagnosis of major depressive disorder
- Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion Criteria:
- Patients with a history of non-compliance as judged by the study investigator
- Patients with a known lack of response to previous treatment with quetiapine
- Patients who have participated in a clinical trial within 4 weeks of randomization
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
To evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in MDD patients with inadequate response to an antidepressant treatment as assessed by the change from randomization to week 6 in the MADRS
|
Sekundære resultatmål
Resultatmål |
---|
To evaluate if quetiapine SR in combination with an antidepressant improves health-related quality of life of patients with MDD, compared to an antidepressant alone
|
To evaluate if quetiapine SR in combination with an antidepressant reduces anxiety symptoms in patients with MDD, compared to an antidepressant alone
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- McIntyre RS, Gorwood P, Thase ME, Liss C, Desai D, Chen J, Bauer M. Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. J Clin Psychopharmacol. 2015 Dec;35(6):706-10. doi: 10.1097/JCP.0000000000000416.
- Weisler R, Montgomery SA, Earley WR, Szamosi J, Eriksson H. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies. J Clin Psychiatry. 2014 May;75(5):520-7. doi: 10.4088/JCP.13m08624.
- Weisler R, McIntyre RS, Bauer M. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. Expert Rev Neurother. 2013 Nov;13(11):1183-200. doi: 10.1586/14737175.2013.846519.
- Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014 Jan;29(1):16-25. doi: 10.1097/YIC.0000000000000011.
- Clayton AH, Locklear JC, Svedsater H, McIntyre RS. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. CNS Spectr. 2014 Apr;19(2):182-96. doi: 10.1017/S1092852913000631. Epub 2013 Sep 25.
- Bauer M, McIntyre RS, Szamosi J, Eriksson H. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. Int J Neuropsychopharmacol. 2013 Sep;16(8):1755-65. doi: 10.1017/S146114571300031X. Epub 2013 May 14.
- Vieta E, Bauer M, Montgomery S, McIntyre RS, Szamosi J, Earley WR, Eriksson H. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2013 Sep 5;150(2):639-43. doi: 10.1016/j.jad.2013.01.052. Epub 2013 Mar 14.
- El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32. doi: 10.1017/S1461145710000015. Epub 2010 Feb 23.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. april 2006
Studiet fullført (Faktiske)
1. juli 2007
Datoer for studieregistrering
Først innsendt
15. mai 2006
Først innsendt som oppfylte QC-kriteriene
15. mai 2006
Først lagt ut (Anslag)
16. mai 2006
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
25. mars 2009
Siste oppdatering sendt inn som oppfylte QC-kriteriene
24. mars 2009
Sist bekreftet
1. mars 2009
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- D1448C00006
- PEARL
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Major depressiv lidelse
-
Shalvata Mental Health CenterUkjentMAjor depressiv lidelseIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.FullførtMajor depressiv lidelse (MDDIndia
-
Gangnam Severance HospitalFullførtMajor depressiv lidelse (MDD)Korea, Republikken
-
Seasons Biotechnology (Taizhou) Co., Ltd.FullførtMajor depressiv lidelse (MDD)India
-
Repurposed Therapeutics, Inc.Ukjent
-
GlaxoSmithKlineFullførtMajor depressiv lidelse (MDD)Forente stater
-
AccexibleRekrutteringMajor depressiv lidelse (MDD)Spania
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Har ikke rekruttert ennåMajor depressiv lidelse (MDD)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RekrutteringMajor depressiv lidelse (MDD)Kina
-
Seasons Biotechnology (Taizhou) Co., Ltd.FullførtMajor depressiv lidelse (MDD)India
Kliniske studier på Quetiapinfumarat
-
Swiss Federal Institute of TechnologyUniversity of Zurich; University Children's Hospital, Zurich; Jomo Kenyatta...Fullført
-
Swiss Federal Institute of TechnologyFullført
-
IPCA Laboratories Ltd.Fullført
-
IPCA Laboratories Ltd.FullførtFastende statIndia
-
University Health Network, TorontoAktiv, ikke rekrutterendeAkutt myeloid leukemi | Myelodysplastiske syndromer | Tilbakefallende kreft | Ildfast kreftCanada
-
University of NebraskaHar ikke rekruttert ennåPerifer arteriell sykdom | Perifere vaskulære sykdommer | Perifer arteriell okklusiv sykdom | Perifer arteriesykdomForente stater
-
Swiss Federal Institute of TechnologyBurgerstein VitamineFullført
-
Isabelle Herter-AeberliBurgerstein VitamineFullførtButikker med lavt jernSveits
-
National Institutes of Health (NIH)Fullført